Antibiotic Treatment for Gram-Positive Infections in Patients with Renal Impairment

Introduction to Antibiotic Selection

The American College of Emergency Physicians and the Infectious Diseases Society of America recommend linezolid as the preferred first-line agent for gram-positive infections in patients with impaired renal function, due to its superior efficacy compared to vancomycin for MRSA infections and no required dose adjustment regardless of renal function 1, 2

For MRSA coverage, the Infectious Diseases Society of America recommends linezolid 600 mg every 12 hours as the first choice, with 100% bioavailability and no renal adjustment needed 1, 2
For VRE coverage, the Infectious Diseases Society of America recommends linezolid 600 mg every 12 hours, which covers both VRE species and requires no renal adjustment 4, 5
For MSSA coverage, the American Heart Association recommends oxacillin or nafcillin with renal dose adjustment, or cefazolin with renal adjustment 6

The National Kidney Foundation recommends assessing renal function and identifying resistance patterns to guide antibiotic selection, with linezolid as the mandatory first choice for CrCl <30 mL/min 1, 2

The FDA recommends daptomycin 10 mg/kg/day, with dose adjustment for renal impairment, and administration every 48 hours when CrCl <30 mL/min 1, 3
The Infectious Diseases Society of America recommends linezolid 600 mg every 12 hours, with no dose adjustment required for renal impairment 1, 2

Linezolid demonstrates superior outcomes compared to vancomycin for MRSA infections, with a microbiological cure rate ratio of 1.17 (95% CI 1.04-1.32) favoring linezolid, and a hospital length of stay 3 days shorter with linezolid 1

The Infectious Diseases Society of America recommends a duration of therapy of 7-14 days for skin/soft tissue infections, minimum 14 days for bacteremia, and 4-6 weeks for endocarditis, with a switch from IV to oral when clinically stable 1

The Centers for Disease Control and Prevention recommend assuming MRSA until proven otherwise for nosocomial/healthcare-associated infections, and considering empiric regimens with linezolid or daptomycin (adjusted) plus anti-gram-negative coverage if polymicrobial suspected 6